Helius Seeks FDA De Novo For Portable Neuromodulation Stimulator For MS Patients
Executive Summary
The FDA has asked the company for more information to support its PoNS therapy for multiple sclerosis patients with gait deficit, including an additional analysis of clinical data and labeling modifications.